Lixte Biotechnology Holdings Inc
$ 7.25
5.22%
11 Jun - close price
- Market Cap 126,052,000 USD
- Current Price $ 7.25
- High / Low $ 7.51 / 6.81
- Stock P/E N/A
- Book Value 0.90
- EPS -1.15
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.46 %
- ROE -1.02 %
- 52 Week High 7.51
- 52 Week Low 0.64
About
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets related to serious common diseases and designs novel compounds to attack those targets. The company is headquartered in East Setauket, New York.
Analyst Target Price
N/A
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-31 | 2025-11-12 | 2025-08-07 | 2025-05-12 | 2025-03-24 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-19 | 2023-11-09 | 2023-08-09 |
| Reported EPS | -0.1783 | -0.3308 | -0.33 | -0.29 | -0.2871 | -0.2746 | -0.4384 | -0.4494 | -0.4318 | -0.4589 | -0.491 | -1.0014 |
| Estimated EPS | None | None | None | 0 | None | None | None | None | None | None | None | None |
| Surprise | 0 | 0 | 0 | -0.29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LIXT
2026-06-12 14:39:47
LIXTE Biotechnology Holdings, Inc. is undergoing a significant transformation by acquiring NOMAD Transportable Power Systems, Inc. and rebranding as NOMAD Power Solutions. The company aims to address the growing bottleneck in electricity delivery for data centers and other industrial sites by providing deployable, utility-grade battery energy storage systems. This strategic pivot positions LIXTE to capitalize on the increasing demand for readily available power, bypassing the slow pace of traditional grid infrastructure development and regulatory hurdles.
2026-06-12 12:39:47
LIXTE Biotechnology Holdings, Inc. (LIXT) is undergoing a significant corporate transformation, shifting from a clinical-stage cancer-drug developer to a power-infrastructure company. This strategic pivot involves acquiring NOMAD Transportable Power Systems, Inc., a leader in deployable, utility-grade battery energy storage, to address the increasing electricity demands of the AI boom. The company aims to provide rapid, deployable power solutions as "NOMAD Power Solutions" to meet the urgent needs of the energy-constrained AI sector.
2026-06-09 23:40:18
This SEC filing (Schedule 13G) discloses that Strategic EP, LLC and Alexander Chase Deitch have acquired beneficial ownership of 5.1% of LIXTE BIOTECHNOLOGY HOLDINGS, INC. common stock. The filing states that Strategic EP, LLC and Alexander Chase Deitch collectively own 774,902 shares with shared voting and dispositive power. The purpose of the investment is passive, not for influencing control of the issuer.
2026-06-05 06:39:43
LIXTE Biotechnology Holdings, Inc. is undergoing a strategic transformation to become an AI energy infrastructure equipment and services platform, aiming to address the escalating power demands of AI and hyperscale data centers. As part of this shift, Stuart D. Porter, founder of Denham Capital, has joined LIXTE’s Board of Directors. The company also announced plans to seek a strategic acquisition partner for its existing clinical-stage pharmaceutical and med-tech operations focused on cancer treatments.
2026-06-04 20:39:34
Lixte Biotechnology Holdings, Inc. has successfully closed a registered direct offering, raising approximately $16.6 million in gross proceeds. The offering included 2,366,503 shares of common stock and Pre-Funded Warrants for an additional 258,859 shares, priced at $6.31 per share or $6.30 per warrant. The company intends to use the net proceeds for general corporate purposes and working capital.
2026-06-04 20:39:34
Lixte Biotechnology (LIXT) has completed a registered direct offering, raising approximately $16.6 million. The company sold 2,366,503 common shares at $6.31 each and issued pre-funded warrants for 258,859 shares at $6.30, with an exercise price of $0.0001. The offering closed on June 4, 2026, and was conducted under an effective shelf registration.
